感染性角膜炎的医学管理方法。
Medical management approach to infectious keratitis.
作者信息
Gokhale Nikhil S
机构信息
Gokhale Eye Hospital and Eyebank, Anant Building, Gokhale Road (S), Dadar West, Mumbai-400 028, India.
出版信息
Indian J Ophthalmol. 2008 May-Jun;56(3):215-20. doi: 10.4103/0301-4738.40360.
Abstract
This section provides guidelines on medical therapy of patients with infectious keratitis. In addition to initial empirical therapy, preferred medications, once the organisms responsible are isolated, are discussed. Atypical mycobacterial keratitis following lasik is described. General guidelines for supportive therapy and follow-up, of these patients are presented. Clinical response to treatment and indications for intervention are discussed. Possible causes and approach to cases refractory to medical therapy are discussed.
摘要
本节提供了感染性角膜炎患者药物治疗的指南。除了初始经验性治疗外，还讨论了一旦分离出致病微生物后的首选药物。描述了准分子激光原位角膜磨镶术（LASIK）后非典型分枝杆菌性角膜炎。介绍了这些患者支持性治疗和随访的一般指南。讨论了治疗的临床反应和干预指征。讨论了药物治疗难治性病例的可能原因及处理方法。
相似文献
1
Medical management approach to infectious keratitis.
Indian J Ophthalmol. 2008 May-Jun;56(3):215-20. doi: 10.4103/0301-4738.40360.
2
Pharmacological treatment for infectious corneal ulcers.
Expert Opin Pharmacother. 2013 Apr;14(5):543-60. doi: 10.1517/14656566.2013.775248. Epub 2013 Feb 27.
3
Photo-activated riboflavin therapy of refractory corneal ulcers.
Cornea. 2012 Oct;31(10):1210-3. doi: 10.1097/ICO.0b013e31823f8f48.
4
Rose Bengal Photodynamic Antimicrobial Therapy for Patients With Progressive Infectious Keratitis: A Pilot Clinical Study.
Am J Ophthalmol. 2019 Dec;208:387-396. doi: 10.1016/j.ajo.2019.08.027. Epub 2019 Sep 5.
5
Conrad Berens Lecture. The management of infectious keratitis as we approach the 21st century.
CLAO J. 1998 Jul;24(3):175-80.
6
Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting.
Ophthalmology. 2014 Jul;121(7):1377-82. doi: 10.1016/j.ophtha.2014.01.011. Epub 2014 Feb 25.
7
Impact of prior therapy on the recovery and frequency of corneal pathogens.
Cornea. 2004 Mar;23(2):158-64. doi: 10.1097/00003226-200403000-00009.
8
Collagen cross-linking and corneal infections.
Curr Opin Ophthalmol. 2013 Jul;24(4):288-90. doi: 10.1097/ICU.0b013e32836229c5.
9
Treatment of refractory infectious keratitis with corneal collagen cross-linking window absorption.
Cornea. 2013 Jun;32(6):e139-40. doi: 10.1097/ICO.0b013e3182886a8c.
10
Investigative modalities in infectious keratitis.
Indian J Ophthalmol. 2009 Mar-Apr;57(2):159. doi: 10.4103/0301-4738.45512.
引用本文的文献
1
Corneal cross-linking for infectious keratitis of various causes: an umbrella review.
BMC Ophthalmol. 2025 Apr 23;25(1):238. doi: 10.1186/s12886-025-04038-3.
2
Enhancing diagnostics: rapid detection of viable trophozoites and cysts using viability PCR assay.
Microbiol Spectr. 2025 Mar 4;13(3):e0181124. doi: 10.1128/spectrum.01811-24. Epub 2025 Feb 7.
3
Successful treatment of Keratitis caused by Mycobacterium chelonae and an overview of previous cases in Europe.
Ann Clin Microbiol Antimicrob. 2024 Oct 9;23(1):92. doi: 10.1186/s12941-024-00752-w.
4
Increased tolerance to commonly used antibiotics in a porcine keratitis model.
Microbiology (Reading). 2024 May;170(5). doi: 10.1099/mic.0.001459.
5
Fungal keratitis after amniotic membrane placement.
Am J Ophthalmol Case Rep. 2023 Dec 7;33:101972. doi: 10.1016/j.ajoc.2023.101972. eCollection 2024 Mar.
6
Three cases of recalcitrant Paecilomyces keratitis in Southern California within a short period.
J Ophthalmic Inflamm Infect. 2024 Jan 4;14(1):1. doi: 10.1186/s12348-023-00380-z.
7
Susceptibility of Ocular to Antibiotics and Multipurpose Disinfecting Solutions.
Antibiotics (Basel). 2021 Oct 3;10(10):1203. doi: 10.3390/antibiotics10101203.
8
Genotype distribution of Acanthamoeba in keratitis: a systematic review.
Parasitol Res. 2021 Sep;120(9):3051-3063. doi: 10.1007/s00436-021-07261-1. Epub 2021 Aug 5.
9
Development of a novel micro-bead force spectroscopy approach to measure the ability of a thermo-active polymer to remove bacteria from a corneal model.
Sci Rep. 2021 Jul 1;11(1):13697. doi: 10.1038/s41598-021-93172-1.
10
Preventing corneal blindness caused by keratitis using artificial intelligence.
Nat Commun. 2021 Jun 18;12(1):3738. doi: 10.1038/s41467-021-24116-6.
本文引用的文献
1
Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
Ophthalmology. 2007 Sep;114(9):1622-9. doi: 10.1016/j.ophtha.2006.12.011.
2
Management of tunnel fungal infection with voriconazole.
J Cataract Refract Surg. 2007 May;33(5):915-7. doi: 10.1016/j.jcrs.2006.12.026.
3
Topical and oral voriconazole in the treatment of fungal keratitis.
Am J Ophthalmol. 2007 Jan;143(1):151-3. doi: 10.1016/j.ajo.2006.07.033. Epub 2006 Aug 31.
4
Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis.
Am J Ophthalmol. 2006 Feb;141(2):282-286. doi: 10.1016/j.ajo.2005.08.081.
5
Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis.
Curr Eye Res. 2005 Dec;30(12):1113-20. doi: 10.1080/02713680500423671.
6
In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil.
Cornea. 2005 Aug;24(6):730-4. doi: 10.1097/01.ico.0000154411.07315.0a.
7
Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis.
Cornea. 2005 May;24(4):449-52. doi: 10.1097/01.ico.0000151539.92865.3e.
8
Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor.
Ophthalmology. 2005 Mar;112(3):466-9. doi: 10.1016/j.ophtha.2004.09.029.
9
Concurrent use of 5% natamycin and 2% econazole for the management of fungal keratitis.
Cornea. 2004 Nov;23(8):793-6. doi: 10.1097/01.ico.0000134193.64357.82.
10
Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.
Arch Ophthalmol. 2004 Jan;122(1):42-7. doi: 10.1001/archopht.122.1.42.
Zotero 插件